LONDON–(BUSINESS WIRE)–May 1, 2018–Market research firm has announced the release of their latest report on the . This new report will provide expert market insights for the forecast period 2018-2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180501005742/en/ Technavio has published a new market research report on the global liver cirrhosis therapeutics market from 2018-2022. (Photo: Business Wire) The report will follow up on Technavio’s previous liver cirrhosis therapeutics market report, presenting detailed market intelligence based on an analysis of the recent trends, market drivers, and challenges, to arrive at actionable insights for the forecast period. The upgraded research report on the global liver cirrhosis therapeutics market is an integral part of Technavio’s portfolio. Technavio covers an extensive range of market research reports on the cardiovascular and metabolic disorders sector, focusing on the development of innovative compounds for novel targets. Some of the topics include biologic therapeutics, peptide therapeutics, inflammatory bowel disease, and type 1 diabetes drugs. This report is available at a USD 1,000 discount for a limited time only: Save more with Technavio. Buy2 reports and get the third for FREE: Global opportunities for growth Technavio’s previous report on the global market projected that the Americas would be the largest market for liver cirrhosis therapeutics by 2020. High incidences of liver diseases such as liver cirrhosis in regions such as the US and Canada is a significant factor that is expected to result in the region’s market share of about 49% by 2020. In the previous… [Read full story]
Leave a Reply